Predictive parameters for ovarian response to hyperstimulation with exogenous gonadotropins after suppression of gonadotropin secretion of the pituitary using a long-acting GnRH agonist.
Individually adapted gonadotropin dosage is more successful than standardized schemes for ovarian stimulation prior to in vitro fertilization and embryo transfer. Unfortunately, differences in ovarian response can not be predicted reliably. In order to develop predictive parameters for ovarian response the data from 99 cycles in 69 patients were analysed retrospectively. Before initiating ovarian stimulation for in vitro fertilization, an untreated menstrual cycle was examined using a commonly used endocrinological screening protocol. The ovaries were then stimulated with exogenous gonadotropins after previous suppression of endogenous gonadotropin secretion using a long-acting GnRH-analogue. The predictive value of this endocrinological screening protocol for ovarian response was evaluated. Ovarian response was defined as the logarithmically transformed ratio of the serum estradiol concentration at ovulation induction, divided by the number of ampoules of exogenous gonadotropins administered. Comparison of the various hormone characteristics with ovarian response led to identification of two distinct groups of patients showing reduced ovarian response: those with elevated serum levels of FSH on the third cycle day (> 9 units/l, P < 0.0001), and those with elevated serum levels of estradiol on the third cycle day (> 190 pmol/l, P < 0.02). Patients with high serum levels of TSH in the TRH test responded poorly to ovarian stimulation (P < 0.05), but also showed significantly higher serum concentrations of FSH (P < 0.01). No parameter correlated positively with ovarian response.
De Geyter
C
C
Woman's Hospital of the University, Münster, Germany.
De Geyter
M
M
Castro
E
E
Bals-Pratsch
M
M
Hanker
J P
JP
Schlegel
W
W
Nieschlag
E
E
Schneider
H P
HP
D000328:Adult; D002452:Cell Count / Q000187:drug effects; D003692:Delayed-Action Preparations; D005260:Female; D006065:Gonadotropins, Pituitary / Q000378:metabolism / Q000494:pharmacology*; D006801:Humans; D008597:Menstrual Cycle / Q000502:physiology*; D009865:Oocytes / Q000187:drug effects; D016471:Ovarian Hyperstimulation Syndrome / Q000139:chemically induced*; D010902:Pituitary Gland / Q000187:drug effects* / Q000378:metabolism; D011237:Predictive Value of Tests; D012189:Retrospective Studies; D012636:Secretory Rate / Q000187:drug effects; D017329:Triptorelin Pamoate / Q000494:pharmacology*
D003692:Delayed-Action Preparations; D006065:Gonadotropins, Pituitary; D017329:Triptorelin Pamoate